O.I. Isaeva, I. Nederlof, M. de Graaf, B. Boeckx, J. Traets, I.A.M. Mandjes, K. Van De Vijver, M. Chelushkin, C. Drukker, M.V. Dongen, G.S. Sonke, S.C. Linn, C.U. Blank, K.E. de Visser, R. Salgado, L. Wessels, T.N. Schumacher, H. Horlings, D. Lambrechts, M. Kok
{"title":"163MO 有肿瘤浸润淋巴细胞的早期三阴性乳腺癌患者的新辅助治疗 nivolumab +/- ipilimumab 诱导的单细胞 T 细胞动态(BELLINI 试验)","authors":"O.I. Isaeva, I. Nederlof, M. de Graaf, B. Boeckx, J. Traets, I.A.M. Mandjes, K. Van De Vijver, M. Chelushkin, C. Drukker, M.V. Dongen, G.S. Sonke, S.C. Linn, C.U. Blank, K.E. de Visser, R. Salgado, L. Wessels, T.N. Schumacher, H. Horlings, D. Lambrechts, M. Kok","doi":"10.1016/j.iotech.2023.100622","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":" 14","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"163MO Single-cell T cell dynamics induced by neoadjuvant nivolumab +/- ipilimumab in early triple negative breast cancer with tumor-infiltrating lymphocytes (BELLINI trial)\",\"authors\":\"O.I. Isaeva, I. Nederlof, M. de Graaf, B. Boeckx, J. Traets, I.A.M. Mandjes, K. Van De Vijver, M. Chelushkin, C. Drukker, M.V. Dongen, G.S. Sonke, S.C. Linn, C.U. Blank, K.E. de Visser, R. Salgado, L. Wessels, T.N. Schumacher, H. Horlings, D. Lambrechts, M. Kok\",\"doi\":\"10.1016/j.iotech.2023.100622\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":192507,\"journal\":{\"name\":\"Immuno-Oncology and Technology\",\"volume\":\" 14\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immuno-Oncology and Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.iotech.2023.100622\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-Oncology and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.iotech.2023.100622","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
163MO Single-cell T cell dynamics induced by neoadjuvant nivolumab +/- ipilimumab in early triple negative breast cancer with tumor-infiltrating lymphocytes (BELLINI trial)